CO5640076A2 - Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento - Google Patents
Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimientoInfo
- Publication number
- CO5640076A2 CO5640076A2 CO05108676A CO05108676A CO5640076A2 CO 5640076 A2 CO5640076 A2 CO 5640076A2 CO 05108676 A CO05108676 A CO 05108676A CO 05108676 A CO05108676 A CO 05108676A CO 5640076 A2 CO5640076 A2 CO 5640076A2
- Authority
- CO
- Colombia
- Prior art keywords
- constipation
- solvate
- treatment
- ibat inhibitor
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- El uso de un inhibidor de IBAT, o su sal, solvato, solvato de tal sal o profármaco farmacéuticamente aceptable, en el tratamiento y/o profilaxis de estreñimiento, en un animal de sangre caliente, tal como el hombre.2.- Una composición farmacéutica que comprende un inhibidor de IBAT, o su sal, solvato, solvato de tal sal o profármaco farmacéuticamente aceptable, en asociación con un diluyente o excipiente farmacéuticamente aceptable para uso en el tratamiento y/o profilaxis del estreñimiento.3.- El uso de un inhibidor de IBAT, o su sal, solvato, solvato de tal sal o profármaco farmacéuticamente aceptable, en la manufactura de un medicamento para uso en el tratamiento y/o profilaxis del estreñimiento, en un animal de sangre caliente, tal como el hombre.4.- Un método de tratamiento y/o profilaxis del estreñimiento, en un animal de sangre caliente, tal como el hombre, necesitado de dicho tratamiento y/o profilaxis, que comprende administrar a dicho animal una cantidad efectiva de un inhibidor de IBAT, o su sal, solvato, solvato de tal sal o profármaco farmacéuticamente aceptable.5.- El uso o método de acuerdo con las reivindicaciones 1-4, en donde el estreñimiento es estreñimiento funcional.6.- El uso o método de acuerdo con las reivindicaciones 1-4, en donde el estreñimiento es síndrome del intestino irritable predominante con estreñimiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0307918.3A GB0307918D0 (en) | 2003-04-05 | 2003-04-05 | Therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5640076A2 true CO5640076A2 (es) | 2006-05-31 |
Family
ID=9956272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05108676A CO5640076A2 (es) | 2003-04-05 | 2005-10-25 | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento |
Country Status (33)
Country | Link |
---|---|
US (1) | US7514421B2 (es) |
EP (2) | EP1610770B1 (es) |
JP (2) | JP4870552B2 (es) |
KR (1) | KR101321577B1 (es) |
CN (1) | CN100366241C (es) |
AR (1) | AR043985A1 (es) |
AT (2) | ATE513550T1 (es) |
AU (1) | AU2004228731B2 (es) |
BR (1) | BRPI0408858A (es) |
CA (1) | CA2520109C (es) |
CO (1) | CO5640076A2 (es) |
CY (2) | CY1107424T1 (es) |
DE (1) | DE602004012079T2 (es) |
DK (2) | DK1894564T3 (es) |
ES (2) | ES2368350T3 (es) |
GB (1) | GB0307918D0 (es) |
HK (1) | HK1085666A1 (es) |
IL (1) | IL170913A (es) |
IS (1) | IS8113A (es) |
MX (1) | MXPA05010706A (es) |
MY (1) | MY137757A (es) |
NO (1) | NO335140B1 (es) |
NZ (1) | NZ542835A (es) |
PL (2) | PL1610770T3 (es) |
PT (2) | PT1610770E (es) |
RU (2) | RU2342928C2 (es) |
SA (1) | SA04250066B1 (es) |
SI (2) | SI1894564T1 (es) |
TW (1) | TWI338577B (es) |
UA (1) | UA84141C2 (es) |
UY (1) | UY28258A1 (es) |
WO (1) | WO2004089350A1 (es) |
ZA (1) | ZA200507996B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
KR101558005B1 (ko) * | 2007-03-08 | 2015-10-06 | 알비레오 에이비 | 2-치환-3-페닐프로피온산 유도체 및 염증성 장 질환 치료에서의 그의 용도 |
JP2012509891A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ,インク. | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
EP2968262A1 (en) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
KR101420315B1 (ko) | 2014-03-19 | 2014-07-17 | 남봉길 | 약학적 액제 조성물 |
CN106573033A (zh) * | 2014-06-25 | 2017-04-19 | Ea制药株式会社 | 固体制剂及其稳定化方法 |
WO2015199147A1 (ja) * | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN109310774A (zh) | 2015-08-17 | 2019-02-05 | 费林股份公司 | 含有匹可硫酸盐和柠檬酸镁的液体制剂 |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11236099B2 (en) | 2017-06-20 | 2022-02-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
MX2020009332A (es) | 2018-03-09 | 2020-10-08 | Elobix Ab | Proceso para la preparacion de elobixibat. |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
AU2020221834A1 (en) | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
WO2022166680A1 (zh) * | 2021-06-25 | 2022-08-11 | 苏州科睿思制药有限公司 | 奥德昔巴特的晶型及其制备方法和用途 |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4771072A (en) | 1985-01-10 | 1988-09-13 | Tanabe Seiyaku Co., Ltd. | Alkoxynaphthalene derivatives |
JPS6310746A (ja) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
DK0489423T3 (da) | 1990-12-06 | 1997-04-14 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler |
EP0597107B1 (en) | 1991-10-17 | 1996-07-03 | Shionogi & Co., Ltd. | Lignan analog, production thereof, and hypolipidemic drug |
EP0549967B1 (de) | 1991-12-20 | 1996-03-13 | Hoechst Aktiengesellschaft | Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
GEP20001968B (en) * | 1992-01-21 | 2000-03-05 | Glaxo Spa | Arilthio Compounds as Antibacterial and Antiviral Agents |
GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
ATE160783T1 (de) | 1992-06-12 | 1997-12-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
JP3411036B2 (ja) | 1993-04-16 | 2003-05-26 | 塩野義製薬株式会社 | リグナン系化合物の製造方法 |
TW289020B (es) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
TW289021B (es) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
NZ331813A (en) | 1996-03-11 | 2001-03-30 | G | Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
JP2002508652A (ja) | 1996-08-23 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 新規なヒト増殖因子 |
JPH1072371A (ja) | 1996-08-28 | 1998-03-17 | Sankyo Co Ltd | 回腸型胆汁酸トランスポーター阻害剤 |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
PL336415A1 (en) | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
ES2198613T3 (es) | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
ATE268758T1 (de) | 1997-04-04 | 2004-06-15 | Aventis Pharma Gmbh | Hypolipidämische propanolaminderivate |
DE19845402B4 (de) | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
HUP0101193A3 (en) | 1997-12-19 | 2001-12-28 | G D Searle & Co Chicago | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
DE19845406C2 (de) | 1998-10-02 | 2001-10-18 | Aventis Pharma Gmbh | Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE19845403B4 (de) | 1998-10-02 | 2005-02-10 | Aventis Pharma Deutschland Gmbh | Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
AU1684400A (en) | 1998-12-11 | 2000-07-03 | Sankyo Company Limited | Substituted benzylamines |
AU776953B2 (en) | 1998-12-23 | 2004-09-30 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
EP1354604A1 (en) | 1998-12-23 | 2003-10-22 | G.D. Searle LLC. | Combinations for cardiovascular indications |
JP2002533415A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ |
CA2356607A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
CA2356422C (en) | 1998-12-23 | 2008-09-16 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
HUP0105409A3 (en) | 1999-02-12 | 2004-11-29 | G D Searle Llc Chicago | 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6287609B1 (en) * | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
TR200002099A3 (tr) | 1999-07-22 | 2001-06-21 | Sankyo Company Limited | Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari |
WO2001034570A1 (fr) | 1999-11-08 | 2001-05-17 | Sankyo Company, Limited | Derives heterocycliques azotes |
WO2001060807A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co. Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
JP2003528830A (ja) | 2000-03-10 | 2003-09-30 | ファルマシア・コーポレーション | テトラヒドロベンゾチエピン類の製造方法 |
AU2001247331A1 (en) | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
US6506921B1 (en) * | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) * | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
GB0201850D0 (en) * | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
-
2003
- 2003-04-05 GB GBGB0307918.3A patent/GB0307918D0/en not_active Ceased
-
2004
- 2004-04-01 AT AT07023058T patent/ATE513550T1/de active
- 2004-04-01 JP JP2006506065A patent/JP4870552B2/ja not_active Expired - Lifetime
- 2004-04-01 ES ES07023058T patent/ES2368350T3/es not_active Expired - Lifetime
- 2004-04-01 PT PT04725081T patent/PT1610770E/pt unknown
- 2004-04-01 BR BRPI0408858-1A patent/BRPI0408858A/pt not_active Application Discontinuation
- 2004-04-01 UA UAA200508758A patent/UA84141C2/ru unknown
- 2004-04-01 PL PL04725081T patent/PL1610770T3/pl unknown
- 2004-04-01 DK DK07023058.6T patent/DK1894564T3/da active
- 2004-04-01 EP EP04725081A patent/EP1610770B1/en not_active Expired - Lifetime
- 2004-04-01 KR KR1020057018959A patent/KR101321577B1/ko active IP Right Grant
- 2004-04-01 SI SI200431710T patent/SI1894564T1/sl unknown
- 2004-04-01 DE DE602004012079T patent/DE602004012079T2/de not_active Expired - Lifetime
- 2004-04-01 US US10/551,999 patent/US7514421B2/en not_active Expired - Lifetime
- 2004-04-01 NZ NZ542835A patent/NZ542835A/en unknown
- 2004-04-01 DK DK04725081T patent/DK1610770T3/da active
- 2004-04-01 WO PCT/GB2004/001396 patent/WO2004089350A1/en active IP Right Grant
- 2004-04-01 EP EP07023058A patent/EP1894564B1/en not_active Expired - Lifetime
- 2004-04-01 ES ES04725081T patent/ES2299832T3/es not_active Expired - Lifetime
- 2004-04-01 PT PT07023058T patent/PT1894564E/pt unknown
- 2004-04-01 SI SI200430662T patent/SI1610770T1/sl unknown
- 2004-04-01 RU RU2005128792/15A patent/RU2342928C2/ru active
- 2004-04-01 CN CNB200480009415XA patent/CN100366241C/zh not_active Expired - Lifetime
- 2004-04-01 MX MXPA05010706A patent/MXPA05010706A/es active IP Right Grant
- 2004-04-01 AU AU2004228731A patent/AU2004228731B2/en not_active Ceased
- 2004-04-01 PL PL07023058T patent/PL1894564T3/pl unknown
- 2004-04-01 CA CA2520109A patent/CA2520109C/en not_active Expired - Lifetime
- 2004-04-01 AT AT04725081T patent/ATE387194T1/de active
- 2004-04-02 MY MYPI20041236A patent/MY137757A/en unknown
- 2004-04-05 SA SA04250066A patent/SA04250066B1/ar unknown
- 2004-04-05 TW TW093109383A patent/TWI338577B/zh not_active IP Right Cessation
- 2004-04-05 UY UY28258A patent/UY28258A1/es not_active Application Discontinuation
- 2004-04-06 AR ARP040101159A patent/AR043985A1/es not_active Application Discontinuation
-
2005
- 2005-09-15 IL IL170913A patent/IL170913A/en unknown
- 2005-09-21 NO NO20054369A patent/NO335140B1/no unknown
- 2005-10-03 ZA ZA200507996A patent/ZA200507996B/xx unknown
- 2005-10-25 CO CO05108676A patent/CO5640076A2/es not_active Application Discontinuation
- 2005-11-01 IS IS8113A patent/IS8113A/is unknown
-
2006
- 2006-05-16 HK HK06105682A patent/HK1085666A1/xx not_active IP Right Cessation
-
2008
- 2008-04-24 CY CY20081100461T patent/CY1107424T1/el unknown
- 2008-07-17 RU RU2008129204/15A patent/RU2482850C2/ru active
-
2011
- 2011-06-07 JP JP2011127175A patent/JP5421326B2/ja not_active Expired - Lifetime
- 2011-09-07 CY CY20111100862T patent/CY1111995T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5640076A2 (es) | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento | |
AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
CO6160236A2 (es) | Inhibidor de quinasa | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
AR041089A1 (es) | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
ECSP024397A (es) | Combinaciones de inihibidores de dipeptildil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus | |
ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
AR066016A1 (es) | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica | |
CO6150136A2 (es) | Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
CO5590913A2 (es) | Terapia de combinacion antivirica | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
BR0309028A (pt) | Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |